Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

P CD19CD20 ALLO1

Next Previous
Drug Profile

P CD19CD20 ALLO1

Alternative Names: CD19/CD20 CAR T-cell therapy - Poseida Therapeutics; Dual CD19/CD20 CAR T therapy - Poseida Therapeutics; Dual P-CD19CD20-ALLO1 Allogeneic CAR-T therapy; P-CD19CD20-ALLO1

Latest Information Update: 12 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Poseida Therapeutics
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I B-cell lymphoma

Most Recent Events

  • 12 Jun 2025 Genentech plans a phase I trial for Multiple sclerosis in USA (IV, Infusion) in August 2025 (NCT07008378)
  • 22 May 2025 Genentech plans a phase I trial for Systemic lupus erythematosus (Treatment-experienced) in September 2025 (IV) (NCT06984341)
  • 09 Dec 2024 Pharmacodynamics data from a preclinical trial in B-cell lymphoma released by Poseida Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top